|
| Study | Language | Sample size | Allocation ratio | Diagnostic criteria | Age (year) | Gender (M:F) | Course of the disease (year) | Severity | (A) Treatment group | (B) Control group I | (C) Control group II | Duration of treatment | Efficacy and safety criteria | Main results |
|
| Wang, 2021 [31] | Chinese | 100 | 1:1 | ①⑥ | A: 69.79 ± 6.52
B: 71.47 ± 6.32 | A: 27:23
B: 26:24 | A: 5.54 ± 2.25
B: 5.39 ± 2.03 | NR | MA + CM | CM (AChEI, 3–6 mg/day dose of rivastigmine) | NR | 90 d | 1. MMSE
2. ADAS-cog
3. Response rate
4. ADL
5. AE | 1. A > B
2. A > B
3. A > B
4. A > B
5. A = B |
| Qin, 2020 [32] | Chinese | 72 | 1:1 | ③ | A: 69.85 ± 5.58
B: 79.74 ± 5.62 | A: 18:16
B: 17:18 | A: 5.41 ± 2.22
B: 5.09 ± 2.48 | NR | MA + CM | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 56 d | 1. MMSE
2. Response rate
3. ADL | 1. A > B
2. A > B
3. A > B |
| Tang, 2020 [33] | Chinese | 60 | 1:1 | ③⑤ | A: 68.63 ± 2.63
B: 69.02 ± 2.41 | A: 14:16
B: 16:14 | A: 1.36 ± 0.47
B: 1.48 ± 0.49 | NR | WA | MA | NR | 28 d | 1. MMSE
2. Response rate
3. ADL | 1. A = B
2. A > B
3. A > B |
| Xia, 2020a [34] | Chinese | 60 | 1:1 | ③ | A: 61 ± 8
B: 62 ± 7 | A: 17:13
B: 18:12 | A: 4.3 ± 2.23
B: 4.58 ± 2.12 | NR | EA + CM | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 56 d | 1. ADAS-cog | 1. A > B |
| Xia, 2020b [35] | Chinese | 60 | 1:1 | ③ | A: 49 ± 11
B: 50 ± 12 | A: 16:14
B: 12:18 | A: 3.79 ± 0.27
B: 4.07 ± 0.27 | NR | EA + CM | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 56 d | 1. MMSE
2. ADL
3. AE | 1. A > B
2. A > B
3. A = B |
| Zhang, 2019 [36] | Chinese | 92 | 1:1 | ④ | A: 72.6 ± 9.2
B: 71.7 ± 8.7 | A: 25:21
B: 27:19 | NR | NR | FA + CM | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 90 d | 1. MMSE
2. Response rate
3. ADL
4. AE | 1. A > B
2. A > B
3. A > B
4. A > B |
| Tang, 2019 [37] | Chinese | 60 | 1:1 | ③⑤ | A: 69 ± 1.6
B: 69.36 ± 2.10 | A: 16:14
B: 15:15 | A: 3.7 ± 1.57
B: 3.36 ± 1.44 | NR | WA | MA | NR | 28 d | 1. MMSE
2. Response rate
3. ADL | 1. A = B
2. A > B
3. A > B |
| Yuan, 2019 [38] | Chinese | 44 | 1:1 | ⑥ | A: 74.8 ± 3.5
B: 75.8 ± 2.8 | A: 11:11
B: 12:10 | NR | NR | SA + CM | CM (AChEI, 5 mg/day dose of donepezil) | NR | 56 d | 1. MMSE
2. Response rate | 1. A = B
2. A > B |
| Feng, 2019 [39] | Chinese | 40 | 1:1 | ③ | A: 68.1 ± 4.8
B: 66.9 ± 4.2 | A: 11:14
B: 12:13 | A: 0.74 ± 0.06
B: 0.72 ± 0.03 | NR | EA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. AE | 1. A = B
2. A > B |
| Wang, 2018 [40] | Chinese | 60 | 1:1 | ①② | A: 62.23 ± 3.63
B: 61.98 ± 3.58 | A: 14:16
B: 13:17 | NR | NR | MA + CM | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 124 d | 1. MMSE
2. ADAS-cog
3. ADL | 1. A > B
2. A > B
3. A > B |
| Jiang, 2018 [41] | Chinese | 40 | 1:1 | ⑥⑦ | 60–80 | 11:9 | 2–12 | Mild and moderate | SA | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. ADL | 1. A < B
2. A < B |
| He, 2018 [42] | Chinese | 60 | 1:1 | ①③ | A: 67.53 ± 5.54
B: 68.37 ± 5.32 | A: 14:16
B: 13:17 | A: 1.82 ± 0.74
B: 1.94 ± 0.84 | NR | WA + CM | CM (AChEI, 5 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. Response rate | 1. A > B
2. A > B |
| Feng, 2017 [43] | Chinese | 40 | 1:1 | ③⑨ | A: 68.10 ± 8.66
B: 68.95 ± 7.16 | A: 12:8
B: 7:13 | A: 4.23 ± 2.26
B: 4.23 ± 2.49 | NR | EA | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. AE | 1. A = B
2. A > B |
| Jia, 2017 [44] | English | 87 | 43:44 | ①② | A: 75.11 ± 6.53
B: 74.5 ± 6.83 | A: 13:30
B: 16:28 | A: 3.2 ± 1.9
B: 3.0 ± 1.4 | A: 24 cases of mild and 19 cases of moderate
B: 23 cases of mild and 21 cases of moderate | MA | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 112 d | 1. ADAS-cog
2. AE | 1. A = B
2. A < B |
| Peng, 2017 [45] | English | 50 | 1:1 | ①⑩ | A: 69.4 ± 5.4
B: 69.5 ± 5.3 | A: 12:13
B: 12:13 | A: 7.5 ± 1.8
B: 7.6 ± 1.7 | NR | EA + CM | CM (AChEI, 0.2 mg/day dose of huperzine) | NR | 30 d | 1. MMSE
2. Response rate | 1. A > B
2. A > B |
| Ben, 2016 [46] | English | 74 | 1:1 | ① | A: 71.5 ± 4.7
B: 70.2 ± 4.6 | A: 16:21
B: 17:20 | A: 3.2 ± 1.9
B: 3.0 ± 1.4 | A: 27 cases of mild and 10 cases of moderate
B: 25 cases of mild and 12 cases of moderate | EA | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. Response rate | 1. A > B
2. A = B |
| Lin, 2016 [47] | Chinese | 90 | 1:1:1 | ①⑧ | A: 73.2 ± 4.81
B: 69.7 ± 5.39
C: 71.6 ± 5.22 | A: 14:16
B: 18:12
C: 17:13 | A: 0.15 ± 0.02
B: 0.16 ± 0.02
C: 0.17 ± 0.02 | NR | SA + CM | SA | CM (AChEI, 5 mg/day dose of donepezil) | 84 d | 1. MMSE
2. ADAS-cog
3. Response rate
4. ADL | 1. A > B > C
2. A > B = C
3. A > B = C
4. A > B > C |
| Wang, 2015 [48] | Chinese | 72 | 1:1 | ② | A: 72.05 ± 3.7
B: 70.31 ± 3.79 | A: 16:20
B: 19:17 | A: 3.33 ± 1.98
B: 2.6 ± 1.51 | NR | EA | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. Response rate | 1. A > B
2. A = B |
| Liu, 2015 [49] | Chinese | 40 | 1:1 | ②⑧ | A: 72.2 ± 4.8
B: 74.4 ± 4.7 | A: 9:11
B: 11:9 | A: 3.38 ± 1.12
B: 2.98 ± 1.07 | NR | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 84 d | Response rate | A = B |
| Li, 2014a [50] | Chinese | 40 | 1:1 | ② | NR | NR | NR | NR | SA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 56 d | 1. MMSE
2. ADL | 1. A > B
2. A > B |
| Wang, 2014 [51] | English | 55 | 27:28 | ① | A: 70.7 ± 9.1
B: 70.3 ± 8.0 | A: 13:15
B: 14:13 | A: 0.48 ± 0.05
B: 0.42 ± 0.09 | NR | SA + CM | CM (AChEI, 5–10 mg/day dose of donepezil) | NR | 20 d | 1. MMSE
2. ADAS-cog
3. Response rate | 1. A > B
2. A = B
3. A > B |
| Ke, 2014 [52] | Chinese | 64 | 1:1 | ①②⑤ | A: 68.28 ± 2.54
B: 68.75 ± 3.40 | A: 15:17
B: 16:16 | A: 1.05 ± 0.22
B: 0.93 ± 0.23 | NR | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 28 d | 1. MMSE
2. Response rate
3. ADL | 1. A > B
2. A = B
3. A > B |
| Ni, 2014 [53] | Chinese | 60 | 1:1 | ①②⑤ | A: 71.8 ± 5.07
B: 70.37 ± 4.96 | A: 15:15
B: 14:16 | A: 1.23 ± 0.4
B: 1.21 ± 0.39 | NR | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 28 d | 1. MMSE
2. Response rate
3. ADL | 1. A > B
2. A = B
3. A > B |
| Zhang, 2014 [54] | Chinese | 60 | 1:1 | ①②⑤ | A: 70.67 ± 4.19
B: 72.43 ± 4.25 | A: 13:17
B: 14:17 | A: 1.02 ± 0.24
B: 1.15 ± 0.23 | NR | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 28 d | 1. MMSE
2. Response rate
3. ADL | 1. A > B
2. A = B
3. A = B |
| Yang, 2014 [55] | Chinese | 60 | 1:1 | ①②⑤ | A: 69.97 ± 5.26
B: 70.23 ± 6.30 | A: 16:14
B: 15:15 | A: 1.24 ± 0.38
B: 1.24 ± 0.43 | NR | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 28 d | 1. MMSE
2. Response rate
3. ADL | 1. A > B
2. A = B
3. A > B |
| Li, 2014b [56] | Chinese | 60 | 1:1 | ①⑧ | 60–70 | A: 17:13
B: 16:14 | NR | A: 14 cases of mild and 16 cases of moderate
B: 15 cases of mild and 15 cases of moderate | MA + CM | CM (AChEI, 5 mg/day dose of donepezil) | NR | 56 d | 1. MMSE
2. ADAS-cog
3. Response rate
4. ADL | 1. A = B
2. A > B
3. A = B
4. A = B |
| Lin, 2014 [57] | Chinese | 36 | 1:1 | ①② | A: 73.44 ± 3.37
B: 74.21 ± 2.68 | A: 7:11
B: 8:10 | A: 1.40 ± 0.62
B: 1.29 ± 0.81 | 36 cases of mild | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. ADAS-cog
3. Response rate
4. ADL | 1. A = B
2. A > B
3. A = B
4. A = B |
| Yan, 2014 [58] | Chinese | 40 | 1:1 | ④ | A: 60–78
B: 60–80 | A: 10:10
B: 8:12 | A: 0–2
B: 0–2 | A: 16 cases of mild and moderate and 4 cases of severe
B: 15 cases of mild and moderate and 5 cases of severe | SA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 84 d | MMSE | A < B |
| Gu, 2014 [59] | Chinese | 160 | 1:1 | ①② | A: 75 ± 7
B: 72 ± 7 | A: 22:50
B: 20:49 | A: 1.27 ± 0.32
B: 1.34 ± 0.24 | NR | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 112 d | 1. MMSE
2. ADAS-cog
3. ADL | 1. A > B
2. A > B
3. A > B |
| Sun, 2013 [60] | Chinese | 70 | 1:1 | ⑧ | A: 64.56 ± 9.05
B: 64.4 ± 9.12 | A: 20:15
B: 14:21 | A: 4.96 ± 2.31
B: 5.16 ± 2.48 | NR | SA + CM | CM (AChEI, 5 mg/day dose of donepezil) | NR | 32 d | 1. MMSE
2. ADL | 1. A > B
2. A > B |
| Yin, 2013 [61] | Chinese | 60 | 1:1 | ①② | 60–85 | 24:36 | NR | NR | SA + CM | CM (AChEI, 5 mg/day dose of donepezil) | NR | 84 d | 1. MMSE
2. ADL | 1. A > B
2. A > B |
| Zhu, 2010 [62] | Chinese | 40 | 1:1 | ① | 72.3 ± 6 | NR | 0.5–3 | Mild and moderate | MA | CM (AChEI, 5 mg/day dose of donepezil) | NR | 56 d | MMSE | A < B |
| Jiang, 2004 [63] | Chinese | 44 | 6:5 | ①⑧ | A: 65.1 ± 6.4
B: 64.3 ± 5.2 | A: 14:10
B: 12:8 | A: 3 ± 1.3
B: 3 ± 1.6 | NR | MA | CM (AChEI, 0.2 mg/day dose of huperzine) | NR | 56 d | 1. MMSE
2. ADL | 1. A = B
2. A = B |
| Dong, 2002 [64] | Chinese | 21 | 11:10 | ① | 46–80 | 20:12 | 0.25–10 | NR | EA | CM (AChEI, 0.2 mg/day dose of huperzine) | NR | 90 d | 1. MMSE
2. ADL | 1. A = B
2. A = B |
|
